Skip to content

Study · Observational study · n = 134 · 2017

2 results

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Iyer KR, Kunecki M, Boullata JI, Fujioka K, Joly F, Gabe S, Pape UF, Schneider SM, Virgili Casas MN, Ziegler TR, Li B, Youssef NN, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition23 Nov 2016Cited by 68 (Europe PMC)

PMID27875291 (opens in a new tab)PMCIDPMC5639959 (opens in a new tab)DOI10.1177/0148607116680791 (opens in a new tab)PepBankPUB-27875291
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    Among 134 adults with SBS-IF, 16 gained oral or enteral autonomy after median PS dependence of 5 years and teduglutide treatment of 89 weeks.

    In plain wordsIn adults with SBS-IF, some patients achieved independence from support during teduglutide treatment.

    Peptide
    Teduglutide
    Outcome
    Not applicableOral or enteral autonomy
    Study

    n = 134

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    0.05 mg/kg/d · Median 89 weeks among patients achieving autonomyAs given in this study (human).

    Measurements

    Patients gaining oral or enteral autonomy
    16 patients
    of 134 patients; post hoc pooled analysis

    Source sentences

    Summary
    Of 134 patients, 16 gained oral or enteral autonomy after a median of 5 years of PS dependence and 89 weeks of teduglutide treatment.
    2 context sentences
    Summary · context
    Post hoc analysis of adult patients who achieved complete PS independence during treatment with teduglutide 0.05 mg/kg/d.
    Summary · context
    Descriptive statistics were used; no between-group comparisons were performed because of the small sample size and lack of comparator.
  2. 02HumanObservational studyEfficacy outcome

    In teduglutide-treated SBS-IF patients, PS independence frequency did not significantly differ between patients with and without colon-in-continuity.

    In plain wordsIn teduglutide-treated SBS-IF patients, support independence frequency did not significantly differ between those with and without colon continuity.

    Peptide
    Teduglutide
    Outcome
    No significant changePS independence by colon continuity
    Study

    n: not reported in source

    Comparator
    Patients without colon-in-continuity
    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    0.05 mg/kg/dAs given in this study (human).

    Source sentences

    Summary
    Most patients who achieved PS independence had colon-in-continuity; however, there was no significant difference in the frequency of PS independence among patients who maintained colon-in-continuity vs those who did not.
    2 context sentences
    Summary · context
    Post hoc analysis of adult patients who achieved complete PS independence during treatment with teduglutide 0.05 mg/kg/d.
    Summary · context
    Descriptive statistics were used; no between-group comparisons were performed because of the small sample size and lack of comparator.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.